Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Yes, a temporary increase in anxiety, jitteriness, or restlessness is common during the first one to two weeks on citalopram, because SSRIs shift serotonin signaling before mood-stabilizing effects fully develop. This "activation" usually peaks early, often eases within two to four weeks, and can be reduced by starting at a low dose, taking the medication at a consistent time, and limiting caffeine and alcohol. Certain signs are not routine, including panic attacks, severe agitation, insomnia that will not break, or any new thoughts of self-harm, which warrant prompt contact with your prescriber, and there are several factors that determine which category you fall into. See below to understand more about typical timelines, warning signs, dose adjustments, and when a different antidepressant may be a better fit.
Because early anxiety on citalopram can look identical whether it is a passing side effect or a signal that your dose or medication needs changing, a few minutes of structured self-assessment is worth far more than guesswork; a free, instant, online symptom check can help you organize your symptoms, gauge urgency, and walk into your next appointment ready to ask the right questions.
Last reviewed for medical accuracy: 09/13/2026
Starting a new antidepressant like citalopram can be both hopeful and a little unsettling. One of the most common questions people ask is whether it's normal to feel increased anxiety during the initial weeks of treatment. Based on trusted clinical guidelines and published research, here’s what you need to know.
Citalopram belongs to a class of medications called selective serotonin reuptake inhibitors (SSRIs). They work by boosting serotonin levels in the brain, which helps improve mood over time. However, during the first one to two weeks, your body is still adapting to higher serotonin availability. This adjustment period can trigger or intensify certain side effects, including anxiety.
Key factors behind early anxiety on citalopram:
Understanding the usual progression can ease concerns and help you recognize when to seek medical advice.
Week 1–2
• Anxiety or restlessness; sometimes jitteriness
• Mild headaches or nausea
• Trouble sleeping or vivid dreams
Week 3–4
• Gradual reduction in physical side effects
• Beginning of mood improvement for some people
• Appetite and sleep patterns may start to normalize
Week 6–8
• Antidepressant benefits often become more noticeable
• Energy levels and motivation may increase
• If anxiety persists or worsens, discuss dose adjustment with your doctor
Most guidelines (for example, from leading psychiatric associations) note that early anxiety usually improves by the end of the second week. If heightened anxiety lingers beyond four weeks, that may signal a need for a different approach.
While your body adjusts, these practical steps can help you stay more comfortable:
• Stick to a routine
– Take citalopram at the same time each day to keep blood levels steady.
– Coordinate doses with meals if mild nausea occurs.
• Practice relaxation techniques
– Deep-breathing exercises or guided meditation can calm racing thoughts.
– Progressive muscle relaxation may ease physical tension tied to anxiety.
• Stay active
– Gentle exercise like walking or yoga boosts endorphins without overstimulation.
– Even short bursts (10–15 minutes) of movement can lift mood.
• Limit caffeine and stimulants
– Coffee, energy drinks, and certain herbal supplements can aggravate jitteriness.
– Opt for decaf or herbal teas if you’re feeling on edge.
• Keep a side-effect diary
– Note when anxiety spikes and what you were doing.
– Bring your diary to follow-up appointments to guide dose or timing adjustments.
It’s crucial to balance patience with vigilance. While mild anxiety is expected early on, certain warning signs call for prompt medical attention:
• Suicidal thoughts or self-harm urges
• Severe panic attacks that disrupt daily activities
• Insomnia lasting more than two weeks despite lifestyle changes
• Signs of serotonin syndrome (see below)
• Any new, unusual, or worsening symptoms
Although rare, serotonin syndrome is a potentially life-threatening reaction caused by excessive serotonin activity. Symptoms can include:
If you suspect serotonin syndrome, seek emergency medical care immediately.
Several peer-reviewed trials and meta-analyses confirm that:
These findings align with prescribing information approved by major regulatory bodies. Always follow your doctor’s instructions on dosing and any recommended titration schedules.
Medication works best when paired with healthy habits and a strong support network:
• Cognitive-behavioral techniques
– Learning to reframe anxious thoughts can speed up your response to citalopram.
– Work with a therapist or explore structured self-help programs.
• Regular social contact
– Talking through worries with friends or family helps you feel less isolated.
– Online support groups for people on SSRIs can also offer reassurance.
• Balanced nutrition
– A diet rich in whole grains, lean protein, fruits, and vegetables supports overall brain health.
– Stay hydrated and avoid excessive alcohol, which can worsen anxiety and interfere with medication.
If you’re unsure whether what you’re feeling is typical, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you sort through your symptoms and decide whether you need to talk with a healthcare professional.
Feeling more anxious during the first two weeks on citalopram is a well-documented and usually temporary part of the adjustment process. With patience, supportive strategies, and open communication with your doctor, most people find that anxiety decreases as the medication takes full effect.
Remember:
Always speak to a doctor about anything that could be life threatening or serious. Your healthcare provider can fine-tune your treatment plan to ensure you get the greatest benefit from citalopram with as few side effects as possible. Take care of yourself—you’re not alone on this journey.
(References)
* Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. doi: 10.1517/13543784.11.10.1477. PMID: 12387707.
* El-Armouche A, Zolk O, Eschenhagen T. [Citalopram]. Dtsch Med Wochenschr. 2003 Oct 24;128(43):2253-6. doi: 10.1055/s-2003-43098. PMID: 14574639.
* Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002. PMID: 17375980.
* Carthy T, Benaroya-Milshtein N, Valevski A, Apter A. Emotional Reactivity and Regulation Following Citalopram Therapy in Children and Adolescents with Anxiety Disorders. J Child Adolesc Psychopharmacol. 2017 Feb;27(1):43-51. doi: 10.1089/cap.2015.0067. Epub 2016 Jan 15. PMID: 26771291.
* Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI. Ziprasidone augmentation for anxious depression. Int Clin Psychopharmacol. 2016 Nov;31(6):341-6. doi: 10.1097/YIC.0000000000000133. PMID: 27306192; PMCID: PMC5039050.
* Amitai M, Kronenberg S, Carmel M, Michaelovsky E, Frisch A, Brent D, Apter A, Chen A, Weizman A, Fennig S. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. J Neural Transm (Vienna). 2016 Nov;123(11):1347-1354. doi: 10.1007/s00702-016-1585-7. Epub 2016 Jun 20. PMID: 27324805.
* Telang S, Walton C, Olten B, Bloch MH. Meta-analysis: Second generation antidepressants and headache. J Affect Disord. 2018 Aug 15;236:60-68. doi: 10.1016/j.jad.2018.04.047. Epub 2018 Apr 9. PMID: 29715610.
* Ji OS, Karalis PG, Daas M, Condon J. Gynecomastia Associated With Citalopram. Prim Care Companion CNS Disord. 2019 Dec 12;21(6):19l02456. doi: 10.4088/PCC.19l02456. Epub 2019 Dec 12. PMID: 31846239.
* Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. Epub 2020 Aug 25. PMID: 32857933; PMCID: PMC7504974.
* Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. PMID: 34587384.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.